nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Pain—Carboplatin—testicular cancer	0.03	0.03	CcSEcCtD
Methylnaltrexone—Redness—Epirubicin—testicular cancer	0.022	0.022	CcSEcCtD
Methylnaltrexone—Redness—Doxorubicin—testicular cancer	0.0203	0.0203	CcSEcCtD
Methylnaltrexone—Stinging—Epirubicin—testicular cancer	0.0183	0.0183	CcSEcCtD
Methylnaltrexone—Erythema—Bleomycin—testicular cancer	0.0171	0.0171	CcSEcCtD
Methylnaltrexone—Stinging—Doxorubicin—testicular cancer	0.0169	0.0169	CcSEcCtD
Methylnaltrexone—Erythema—Dactinomycin—testicular cancer	0.016	0.016	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.0156	0.0156	CcSEcCtD
Methylnaltrexone—Pain—Chlorambucil—testicular cancer	0.0154	0.0154	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Chlorambucil—testicular cancer	0.0148	0.0148	CcSEcCtD
Methylnaltrexone—Injection site reaction—Epirubicin—testicular cancer	0.0147	0.0147	CcSEcCtD
Methylnaltrexone—Erythema—Ifosfamide—testicular cancer	0.0146	0.0146	CcSEcCtD
Methylnaltrexone—Abdominal pain—Chlorambucil—testicular cancer	0.0143	0.0143	CcSEcCtD
Methylnaltrexone—Pain—Vinblastine—testicular cancer	0.0142	0.0142	CcSEcCtD
Methylnaltrexone—Oedema—Bleomycin—testicular cancer	0.014	0.014	CcSEcCtD
Methylnaltrexone—Injection site reaction—Doxorubicin—testicular cancer	0.0136	0.0136	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vinblastine—testicular cancer	0.0135	0.0135	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vinblastine—testicular cancer	0.0131	0.0131	CcSEcCtD
Methylnaltrexone—Oedema—Dactinomycin—testicular cancer	0.013	0.013	CcSEcCtD
Methylnaltrexone—Erythema—Cisplatin—testicular cancer	0.0126	0.0126	CcSEcCtD
Methylnaltrexone—Flatulence—Cisplatin—testicular cancer	0.0124	0.0124	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.0124	0.0124	CcSEcCtD
Methylnaltrexone—Diarrhoea—Chlorambucil—testicular cancer	0.0124	0.0124	CcSEcCtD
Methylnaltrexone—Pain—Bleomycin—testicular cancer	0.012	0.012	CcSEcCtD
Methylnaltrexone—Oedema—Ifosfamide—testicular cancer	0.0119	0.0119	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ifosfamide—testicular cancer	0.0117	0.0117	CcSEcCtD
Methylnaltrexone—Skin disorder—Ifosfamide—testicular cancer	0.0116	0.0116	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Ifosfamide—testicular cancer	0.0116	0.0116	CcSEcCtD
Methylnaltrexone—Vomiting—Chlorambucil—testicular cancer	0.0115	0.0115	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vinblastine—testicular cancer	0.0113	0.0113	CcSEcCtD
Methylnaltrexone—Pain—Dactinomycin—testicular cancer	0.0112	0.0112	CcSEcCtD
Methylnaltrexone—Dizziness—Vinblastine—testicular cancer	0.0109	0.0109	CcSEcCtD
Methylnaltrexone—Nausea—Chlorambucil—testicular cancer	0.0107	0.0107	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.0107	0.0107	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dactinomycin—testicular cancer	0.0107	0.0107	CcSEcCtD
Methylnaltrexone—Vomiting—Vinblastine—testicular cancer	0.0105	0.0105	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.0103	0.0103	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dactinomycin—testicular cancer	0.0103	0.0103	CcSEcCtD
Methylnaltrexone—Oedema—Cisplatin—testicular cancer	0.0103	0.0103	CcSEcCtD
Methylnaltrexone—Pain—Ifosfamide—testicular cancer	0.0102	0.0102	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Cisplatin—testicular cancer	0.0101	0.0101	CcSEcCtD
Methylnaltrexone—Skin disorder—Cisplatin—testicular cancer	0.01	0.01	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Cisplatin—testicular cancer	0.00996	0.00996	CcSEcCtD
Methylnaltrexone—Nausea—Vinblastine—testicular cancer	0.00983	0.00983	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00978	0.00978	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00977	0.00977	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ifosfamide—testicular cancer	0.00945	0.00945	CcSEcCtD
Methylnaltrexone—Skin disorder—Etoposide—testicular cancer	0.00917	0.00917	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Etoposide—testicular cancer	0.00912	0.00912	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dactinomycin—testicular cancer	0.00892	0.00892	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00889	0.00889	CcSEcCtD
Methylnaltrexone—Vomiting—Bleomycin—testicular cancer	0.00889	0.00889	CcSEcCtD
Methylnaltrexone—Pain—Cisplatin—testicular cancer	0.00881	0.00881	CcSEcCtD
Methylnaltrexone—Nausea—Bleomycin—testicular cancer	0.0083	0.0083	CcSEcCtD
Methylnaltrexone—Vomiting—Dactinomycin—testicular cancer	0.00829	0.00829	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ifosfamide—testicular cancer	0.00818	0.00818	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Etoposide—testicular cancer	0.00815	0.00815	CcSEcCtD
Methylnaltrexone—Pain—Etoposide—testicular cancer	0.00807	0.00807	CcSEcCtD
Methylnaltrexone—Dizziness—Ifosfamide—testicular cancer	0.0079	0.0079	CcSEcCtD
Methylnaltrexone—Nausea—Dactinomycin—testicular cancer	0.00775	0.00775	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Etoposide—testicular cancer	0.00772	0.00772	CcSEcCtD
Methylnaltrexone—Vomiting—Ifosfamide—testicular cancer	0.0076	0.0076	CcSEcCtD
Methylnaltrexone—Abdominal pain—Etoposide—testicular cancer	0.00746	0.00746	CcSEcCtD
Methylnaltrexone—Nausea—Ifosfamide—testicular cancer	0.0071	0.0071	CcSEcCtD
Methylnaltrexone—Diarrhoea—Cisplatin—testicular cancer	0.00705	0.00705	CcSEcCtD
Methylnaltrexone—Erythema—Methotrexate—testicular cancer	0.00693	0.00693	CcSEcCtD
Methylnaltrexone—Vomiting—Cisplatin—testicular cancer	0.00655	0.00655	CcSEcCtD
Methylnaltrexone—Erythema—Epirubicin—testicular cancer	0.00648	0.00648	CcSEcCtD
Methylnaltrexone—Diarrhoea—Etoposide—testicular cancer	0.00646	0.00646	CcSEcCtD
Methylnaltrexone—Flatulence—Epirubicin—testicular cancer	0.00639	0.00639	CcSEcCtD
Methylnaltrexone—Dizziness—Etoposide—testicular cancer	0.00624	0.00624	CcSEcCtD
Methylnaltrexone—Nausea—Cisplatin—testicular cancer	0.00612	0.00612	CcSEcCtD
Methylnaltrexone—Vomiting—Etoposide—testicular cancer	0.006	0.006	CcSEcCtD
Methylnaltrexone—Erythema—Doxorubicin—testicular cancer	0.006	0.006	CcSEcCtD
Methylnaltrexone—Flatulence—Doxorubicin—testicular cancer	0.00591	0.00591	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00586	0.00586	CcSEcCtD
Methylnaltrexone—Nausea—Etoposide—testicular cancer	0.00561	0.00561	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Methotrexate—testicular cancer	0.00554	0.00554	CcSEcCtD
Methylnaltrexone—Skin disorder—Methotrexate—testicular cancer	0.00549	0.00549	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00548	0.00548	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Methotrexate—testicular cancer	0.00546	0.00546	CcSEcCtD
Methylnaltrexone—Oedema—Epirubicin—testicular cancer	0.00529	0.00529	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Epirubicin—testicular cancer	0.00519	0.00519	CcSEcCtD
Methylnaltrexone—Skin disorder—Epirubicin—testicular cancer	0.00514	0.00514	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Epirubicin—testicular cancer	0.00511	0.00511	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00507	0.00507	CcSEcCtD
Methylnaltrexone—Oedema—Doxorubicin—testicular cancer	0.00489	0.00489	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00488	0.00488	CcSEcCtD
Methylnaltrexone—Pain—Methotrexate—testicular cancer	0.00483	0.00483	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Doxorubicin—testicular cancer	0.0048	0.0048	CcSEcCtD
Methylnaltrexone—Skin disorder—Doxorubicin—testicular cancer	0.00475	0.00475	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Doxorubicin—testicular cancer	0.00473	0.00473	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Methotrexate—testicular cancer	0.00462	0.00462	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00457	0.00457	CcSEcCtD
Methylnaltrexone—Pain—Epirubicin—testicular cancer	0.00452	0.00452	CcSEcCtD
Methylnaltrexone—Abdominal pain—Methotrexate—testicular cancer	0.00447	0.00447	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Epirubicin—testicular cancer	0.00433	0.00433	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.00423	0.00423	CcSEcCtD
Methylnaltrexone—Pain—Doxorubicin—testicular cancer	0.00419	0.00419	CcSEcCtD
Methylnaltrexone—Abdominal pain—Epirubicin—testicular cancer	0.00418	0.00418	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.004	0.004	CcSEcCtD
Methylnaltrexone—Abdominal pain—Doxorubicin—testicular cancer	0.00387	0.00387	CcSEcCtD
Methylnaltrexone—Diarrhoea—Methotrexate—testicular cancer	0.00387	0.00387	CcSEcCtD
Methylnaltrexone—Dizziness—Methotrexate—testicular cancer	0.00374	0.00374	CcSEcCtD
Methylnaltrexone—Diarrhoea—Epirubicin—testicular cancer	0.00362	0.00362	CcSEcCtD
Methylnaltrexone—Vomiting—Methotrexate—testicular cancer	0.00359	0.00359	CcSEcCtD
Methylnaltrexone—Dizziness—Epirubicin—testicular cancer	0.0035	0.0035	CcSEcCtD
Methylnaltrexone—Vomiting—Epirubicin—testicular cancer	0.00336	0.00336	CcSEcCtD
Methylnaltrexone—Nausea—Methotrexate—testicular cancer	0.00336	0.00336	CcSEcCtD
Methylnaltrexone—Diarrhoea—Doxorubicin—testicular cancer	0.00335	0.00335	CcSEcCtD
Methylnaltrexone—Dizziness—Doxorubicin—testicular cancer	0.00324	0.00324	CcSEcCtD
Methylnaltrexone—Nausea—Epirubicin—testicular cancer	0.00314	0.00314	CcSEcCtD
Methylnaltrexone—Vomiting—Doxorubicin—testicular cancer	0.00311	0.00311	CcSEcCtD
Methylnaltrexone—Nausea—Doxorubicin—testicular cancer	0.00291	0.00291	CcSEcCtD
